Capricor Therapeutics (CAPR) shares plummeted approximately 81% over the past 30 days, falling from $22.43 on July 6 to $4.17 by August 4, 2026. The collapse was triggered by an FDA briefing document released July 27 that challenged the statistical validity of Deramiocel's Phase 3 HOPE-3 trial results, contradicting Capricor's earlier positive characterization.

First Tracks Biotherapeutics shares surged approximately 130% over the past 30 days, climbing from around $20.04 on July 6 to $46.01 by August 4, 2026. The stock hit multiple all-time highs during the period, driven by a powerful combination of clinical validation catalysts, analyst upgrades, and favorable sector momentum in biotech.

Forte Biosciences (FBRX) surged approximately 266% over the past 30 days, climbing from around $20.92 to $76.56 as of August 4, 2026. The primary catalyst was positive Phase 1b vitiligo data for lead candidate FB102, which sent shares soaring 78% in a single session on July 9.

CG Oncology (CGON) is a late-stage clinical biopharmaceutical company focused on developing cretostimogene grenadenorepvec, an investigational oncolytic immunotherapy for bladder cancer. The stock has traded in a relatively contained range over the past 30 days, with a modest gain of approximately 3%, reflecting a period of consolidation following stronger year-to-date gains.

Xenon Pharmaceuticals shares traded at $64.01 as of early August 2026, reflecting a modest gain of approximately 5.7% over the trailing 30-day period. The company's lead asset, azetukalner, delivered highly positive Phase 3 X-TOLE2 data in focal onset seizures and management expects to submit a New Drug Application to the FDA in the third quarter of 2026.

Scholar Rock (SRRK) shares fell approximately 13.7% over the last 30 days, declining from $55.36 on July 6, 2026, to $47.79 as of August 4, 2026. The primary catalyst behind the sell-off was an announcement on July 20 that the European Medicines Agency's (EMA) CHMP opinion on apitegromab hinges on the FDA's classification of the Catalent Indiana manufacturing facility, introducing fresh regulatory uncertainty.

Target in focus: Piper Sandler's $77 price target represents roughly 40% upside from Moderna's recent close of $55.14, making it the most bullish Wall Street objective currently on the table. Strongest bullish factors: An imminent FDA decision on the company's mRNA flu vaccine (mFLUSIVA), advancing oncology pipeline assets including the closely watched intismeran autogene melanoma program, and a fortified balance sheet with approximately $5.96 billion in pro forma cash.

Alnylam Pharmaceuticals (ALNY) shares plunged approximately 29.6% over the past 30 days, falling from $312.78 on July 2 to $220.33 as of the latest close on August 3, 2026. The primary catalyst was the company's July 30 Q2 2026 earnings report, which featured a $200 million cut to full-year TTR product revenue guidance, triggering a single-day selloff of roughly 28%.

Revenue exceeded expectations: Vertex reported $3.33 billion in total revenue for the second quarter, a 12% year-over-year increase that surpassed consensus estimates of roughly $3.19–$3.23 billion. Earnings per share landed near consensus: Non-GAAP (Generally Accepted Accounting Principles) diluted EPS (Earnings Per Share) came in at $4.73, compared to $4.52 in the prior-year quarter and in line with most analyst forecasts.

TGTX plunged approximately -11.2% during Monday's regular trading session, falling from Friday's close of $52.03 to around $46.23, after reporting Q2 2026 earnings that badly missed expectations. The primary catalyst was a severe earnings miss: TG Therapeutics reported EPS of just $0.05, far below the consensus estimate of $0.31–$0.41, as surging R&D expenses (+217.5% YoY) and SG&A costs eroded profitability.

KRYS fell -8.99% to approximately $310.45 from the prior session close of $341.12 during regular market hours on August 3. The decline followed the company's release of Q2 2026 financial results, which showed an EPS miss at $1.79 versus consensus estimates near $1.91.

Price target: $100 per share — a psychological round number and widely cited level among Wall Street analysts covering BBIO. Bullish drivers: Strong commercial launch of Attruby (acoramidis) for ATTR-CM, a promising late-stage pipeline including BBP-418 for LGMD, and near-unanimous analyst Buy ratings.

Vertex Pharmaceuticals (VRTX) is scheduled to report second-quarter 2026 financial results after the market closes on Monday, August 3, with a conference call to follow at 4:30 p.m. ET. Wall Street consensus estimates point to earnings per share (EPS) of approximately $4.72 to $4.75 on revenue of roughly $3.21 billion to $3.23 billion , representing year-over-year growth of about 5% and 8–9%, respectively.

Price Target: $30.00 per share — the highest analyst price target on Wall Street, representing approximately 60% upside from the stock's recent closing price near $18.68. Strongest Bullish Factors: A robust clinical pipeline targeting the RAS/MAPK pathway, encouraging Phase 1 data for ERAS-0015, and a cash runway extending into the second half of 2028 following a sizable public offering.

The $135 price target represents the highest Wall Street target for SYRE, set by Deutsche Bank, implying approximately 33% upside from the current price near $101.50. Strong bullish factors include a unanimous analyst consensus rating of Strong Buy, a broad pipeline targeting multi-billion-dollar IBD markets, and significant institutional ownership above 90%.

CRNX currently trades near $83.63, just below the $85 per-share cash acquisition price offered by Vertex Pharmaceuticals in July 2026. Reaching $90 would require a competing bid, a revised offer, or a deal-break scenario that unlocks standalone value above the current takeout price.

Bio-Techne shares rose approximately 1.5% over the last 30 days, trading near $72 as the stock hovers just below Merck KGaA's $73-per-share acquisition offer. The pending $11.3 billion all-cash acquisition by Merck KGaA, announced in late June 2026, has become the dominant force anchoring TECH's valuation and muting volatility.

PHAT shares plunged -18.04% to $9.54 intraday after the company reported Q2 2026 results and slashed its full-year revenue guidance The sell-off began premarket at -8.93% and accelerated sharply during regular trading as investors digested the weaker outlook

INO plummeted -44.23% during regular trading on July 30, following a -21% pre-market decline, after the company priced a deeply dilutive public offering after the July 29 close. The primary catalyst is a $20 million underwritten offering of 21.05 million common shares plus warrants to purchase an additional 42.11 million shares at a combined price of just $0.95 per share — a steep discount to the $1.04 prior close.

ALNY shares plunged -23.94% during Thursday's regular session, sinking from a previous close of $286.62 to approximately $218, after the company reported Q2 2026 results before market open. The primary catalyst was a sharp cut to full-year TTR net product revenue guidance, lowered to $4.2B–$4.5B from the prior range of $4.4B–$4.7B, citing slower ATTR-CM launch uptake and normalization of pent-up demand.